Problems of Social Hygiene, Public Health and History of MedicineProblems of Social Hygiene, Public Health and History of Medicine0869-866X2412-2106Joint-Stock Company Chicot42710.32687/0869-866X-2020-28-s2-1168-1175Научная статьяComparative characteristics of types of medical technologies assessmentHolovnya-VoloskovaM. E.-TolkushinA. G.-KornilovaE. B.-ZavyalovA. A.-State Budgetary Institution “Research Institute for Healthcare Organization and Medical Management of Moscow Healthcare Department”Medical University of Warsaw15122020281168117506042021Copyright © 2020,2020This article presents the results obtained during the analysis of different types of health technology assessment (HTA). In the world HTA agencies can be organized at the national (federal), regional or local levels; they can have various levels of dependence on public authorities (independent, public, dependent), various sources of financing (state, mixed). The nature of the tasks and the range of powers of the institutions for HTA differ: regulatory, organizational or advisory. They themselves can initiate HTA (proactive), or they can conduct HTA at the suggestion of the applicants and analyze the quality of the HTA reports provided (reactively). HTA can be focused on economic assessment, comparative clinical assessment, as well as balanced, both on economic and comparative clinical assessments. HTA may be conducted on drugs, medical devices, and other medical technologies. The methods for conducting HTA significantly depend on its subject. In terms of the scope of the assessment, it is possible to single out full OMT, mini-OMT and express-OMT, as well as fast-track-OMT, proposed by the HTA agency in the UK. The final users of HTA (administration, suppliers, patients) and its perceptions (instrumental, conceptual, or formal) are specified. The impact of HTA on decision-making is progressively increasing, as the number of medical technologies that should be assessed to maintain budget discipline is increasing. The versatility of HTA indicates its universality and can contribute to the further expansion of its application at various levels of medical care around the world.health technology assessmentexpress-HTAmini-HTAHTA-agenciesоценка медицинских технологийоценка технологий здравоохраненияоценка технологий в здравоохраненииучреждения по оценке медицинских технологий[World Health Organization. Health technology assessment of medical devices. 2011. Режим доступа: https://www.who.int/medical_devices/assessment/en/ (дата обращения 08.06.2020).][Воробьев П. А., Авксентьева М. В., Юрьев А. С. Клинико-экономический анализ (оценка, выбор медицинских технологий и управление качеством медицинской помощи). М.: Ньюдиамед; 2004.][Introduction to mini-HTA - a management and decision support tool for the hospital service. Danish Center for Health Technology Assessment and Assessment (DACEHTA), Bruges National Health Council (eds.). Copenhagen; 2005. Available at: https://www.sst.dk/~/media/47C62A769EBC4E80A153F986C5348F55.ashx.][Авксентьева М. В., Омельяновский В. В. Международный опыт оценки технологий в здравоохранении. Медицинские технологии. Оценка и выбор. 2010;(1):52-8.][Хабриев Р. У., Суходолов А. П., Спасенников Б. А., Безмельницына Л. Ю., Мешков Д. О. Система принятия решений в программе льготного лекарственного обеспечения. Известия Байкальского государственного университета. 2018;28(1):6-11.][Khabriev R., Meshkov D., Bezmelnitsyna L., Cherkasov S., Berseneva E., Scahill S. Pharmaceutical policy in Russia. Pharmaceutical policy in countries with developing healthcare systems. 2017;12:261-85.][Омельяновский В. В., Никитина А. В., Лемешко В. А., Хачатрян Г. Р. Лекарственное обеспечение и оценка технологий здравоохранения во Франции. Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология. 2020;13(1):71-83. doi: 10.17749/2070-4909.2020.13.1.71-83][Хачатрян Г. Р., Омельяновский В. В., Мельникова Л. С., Ратушняк С. С. Международный опыт организации и финансового обеспечения агентств по оценке технологий здравоохранения. Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология. 2019;12(2):146-54. doi: 10.17749/2070-4909.2019.12.2.146-154).][del Llano-Señarís J. E., Campillo-Artero C. Health technology assessment and health policy today: a multifaceted view of their unstable crossroads. Springer Books, Springer; 2015: edition 127.][Health Technology Assessment (HTA) in the Nordic countries introduction to and status of HTA’s role in the value chain of medical technology. 2017. Режим доступа: https://www.nordicinnovation.org/sites/default/files/inline-images/Health%20Technology%20Assessment%20%28HTA%29%20in%20the%20Nordic%20countries.pdf][Agency for care effectiveness. Government of Singapore. Режим доступа: http://www.ace-hta.gov.sg/about-us.html.][Husereau D., Henshall C., Sampietro-Colom L., Thomas S. Changing health technology assessment paradigms? Int. J. Technol. Assess. Health Care. 2016;32(4):191-9. doi: 10.1017/s0266462316000386][Danko D. Health technology assessment in middle-income countries: recommendations for a balanced assessment system. J. Mark. Access Health Policy 2014;2(1):23181. doi: 10.3402/jmahp.v2.23181][Власов В. В., Плавинский С. Л. Варианты лекарственного обеспечения для России: уроки стран Европы и всего мира. М.: Медиасфера; 2013. С. 108.][Baran-Kooiker A., Czech M., Kooiker C. Multi-Criteria Decision Analysis (MCDA) Models in Health Technology Assessment of orphan drugs - a systematic literature review. Next steps in methodology development? Front. Public Health. 2018;6:287. doi: 10.3389/fpubh.2018.00287][Kidholm K., Ehlers L., Korsbek L., Kjærby R., Beck M. Assessment of the quality of mini-HTA. Int. J. Technol. Assess. Health Care. 2009;25(1):42-8. doi: 10.1017/s0266462309090060][Charlton V. NICE and Fair? Health Technology Assessment policy under the UK’s National Institute for Health and Care Excellence, 1999-2018. Health Care Anal. 2020;28(3):193-227. doi: 10.1007/s10728-019-00381-x][Pecchia L., Craven M. P. Early stage Health Technology Assessment (HTA) of biomedical devices. The MATCH experience. IFMBE Proceedings. 2013;39:1525-8. doi: 10.1007/978-3-642-29305-4_401][Blüher M., Saunders S. J., Mittard V., Torrejon Torres R., Davis J. A., Saunders R. Critical review of European Health - Economic Guidelines for the Health Technology Assessment of medical devices. Front. Med. 2019;6:278. doi: 10.3389/fmed.2019.00278][Polisena J., Castaldo R., Ciani O., Federici C., Borsci S., Ritrovato M., et al. Health technology assessment methods guidelines for medical devices: how can we address the gaps? The international federation of medical and biological engineering perspective. Int.l J. Technol. Assess. Health Care. 2018;34(3):276-89. doi: 10.1017/s0266462318000314][Tarricone R., Torbica A., Drummond M. Challenges in the assessment of medical devices: the MedtecHTA project. Health Econ. 2017;26:5-12. doi: 10.1002/hec.3469][Hivon M., Lehoux P., Denis J. L., Tailliez S. Use of health technology assessment in decision making: coresponsibility of users and producers? Int. J. Technol. Assess. Health Care. 2005;21(2):268-75. doi: 10.1017/s0266462305050361]